Figure 8
From: Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
Gedatolisib increases survival of mice in a sorafenib-resistant PDX model. (a) Colony-forming units assay from sorafenib-resistant primary AML cells treated with either 1 or 10 nM sorafenib in combination with 50 nM gedatolisib. Results represent the average of triplicate assays. Error bars represent mean±s.e.m. (b) Proportion of circulating human CD45-positive AML cells in peripheral blood from four mice per group 58 days post injection. P-value calculated using Mann–Whitney test. Error bars represent mean±s.e.m. (c) Kaplan–Meier curves showing overall survival of mice (n=7 for each group) transplanted with sorafenib-resistant primary cells harvested from a sorafenib-treated patient with AML. Statistical significance determined by log-rank (Mantel–Cox) test. *P-value⩽0.05 by comparison with vehicle-treated group.
